After Rejection, Sanofi Threatens Hostile Bid For Medivation
Biopharmaceutical firm Medivation Inc. said its board of directors unanimously rejected Sanofi SA's $9.3 billion all-cash buyout offer, which it claims is inadequate, but the French drugmaker countered Friday by saying...To view the full article, register now.
Already a subscriber? Click here to view full article